Advanced searches left 3/3

Metastatic Melanoma Immunotherapy - U.S. Department of Veterans Affairs

Summarized by Plex Scholar
Last Updated: 03 November 2021

* If you want to update the article please login/register

Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma.

Metastatic melanoma is tough to deal with, and often hints a grim diagnosis. Systemic immunotherapy and targeted agents are arising as the essential of treatment for metastatic melanoma. Collecting proof recommends that in addition to efficient locoregional control, radiation therapy might generate immune activation and development of T lymphocytes recognizing melanocyte-specific antigens including turned on cytotoxic T lymphocytes that can potentially kill melanoma cells. Below, we assess the potential pledge of ablative radiation treatment in the era of contemporary immunotherapy by presenting an individual with metastatic melanoma who remained condition free for over 3 years after an initial medical diagnosis of innovative metastatic melanoma with brain, subcutaneous cells, mesenteric, pelvic, and retroperitoneal involvement. The patient stopped working preliminary stereotactic radiosurgery, yet replied to whole-brain RT in combination with interleukin-2 immunotherapy. Therefore, combination RT with immunotherapy might be synergistic by advertising the release and processing of melanoma antigens that can be provided by dendritic cells.

Source link: https://doi.org/10.1097/COC.0b013e3182940dc3

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions